Daiichi Sankyo Unit Says Rival Infringed IP As Trial Opens
Counsel for a Daiichi Sankyo subsidiary told a California federal jury during trial openings on Monday that Novartis owes royalties for selling drugs that allegedly infringe its billion-dollar skin cancer treatment...To view the full article, register now.
Already a subscriber? Click here to view full article